IHM
BMRN icon

Iguana Healthcare Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Iguana Healthcare Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-25,000
Closed -$2.27M – 70
2017
Q2 		$2.27M Buy
+25,000
New +$2.27M 1.28% 33
2014
Q2 		– Sell
-40,000
Closed -$2.73M – 66
2014
Q1 		$2.73M Buy
+40,000
New +$2.95M 1.26% 29

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Iguana Healthcare Management's BMRN Position: Q2 2016 in Review

Iguana Healthcare Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2016, closing a stake of 30,000 shares — an estimated $2.47M sold.

Iguana Healthcare Management first reported a position in BMRN in Q1 2014 and held it in 4 quarters. The position peaked at $2.47M in Q1 2016. 392 funds tracked by Wall St. Rank hold BMRN as of Q2 2016.

  • Iguana Healthcare Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Iguana Healthcare Management sold 30,000 BioMarin Pharmaceuticals shares in Q2 2016, an estimated $2.47M.
  • Iguana Healthcare Management first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 4 quarters.
  • Iguana Healthcare Management's BioMarin Pharmaceuticals position peaked at $2.47M in Q1 2016.
  • 392 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2016.

Based on Iguana Healthcare Management's 13F filing for Q2 2016, filed 15 Aug 2016.